MDM2 and acute myeloid leukemia: In this context, we have adapted the TP53 wild-type acute myeloid leukaemia (AML) cell lines MV4-11, OCI-AML-2, OCI-AML-3, and SIG-M5 to the MDM2 inhibitor nutlin-3 in multiple independent experiments[102].